Shenfu injection for heart failure based on the AMSTAR-2, PRISMA, and GRADE tools

Abstract

Background: Evidence of the efficacy of Shenfu injection (SFI) in the treatment of heart failure (HF) is inconsistent. This study aimed to strictly evaluate the methodological quality, reporting quality, and evidence quality of systematic reviews (SRs) and meta-analyses (MAs) on the efficacy of SFI. Methods: From inception to December 2020, using standardized search strategies, we searched for relevant SRs and MAs in the following seven databases: Cochrane library, Embase, PubMed, SinoMed, China National Knowledge Infrastructure (CNKI), Wanfang Database, and VIP Database. The Appraisal Tool for Systematic Reviews of Randomized and Observational Studies 2 (AMSTAR-2) and Preferred Reporting Item for Systematic Reviews and Meta-Analyses (PRISMA) tools were used to evaluate the methodological and reporting quality of SRs, respectively. The quality of results was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tool. If necessary, we conducted quantitative synthesis or descriptive analysis of the original data. Results: There were 12 SRs/MAs involving 302 original randomized controlled trials (RCTs) and more than 22,445 participants (the total number was not mentioned in 1 study). The treatment group was classified as SFI combined with western medicine (WM), while the control group was WM alone. The methodological quality of all the literatures was very low, and the quality of reports was relatively good, with an average PRISMA score of 18.25 points. We evaluated 52 outcomes, of which 3 were moderate quality, 13 were low quality, and the rest were very low quality. Low quality evidences indicated that the clinical efficacy of SFI combined with WM for HF was better than that of WM, which can improve the quality of life and cardiac function of patients. Conclusions: It appeared that SFI was effective in the treatment of HF. Due to the low quality of methodology and reports in the literature, we cannot be sure of the results. We strongly recommend that more high-level RCTs be carried out in the future. Besides, researchers should strictly comply with the AMSTAR-2, PRISMA, and GRADE guidelines for SRs.